期刊
JOURNAL OF INFECTION
卷 83, 期 4, 页码 490-495出版社
W B SAUNDERS CO LTD
DOI: 10.1016/j.jinf.2021.07.030
关键词
Chronic pulmonary aspergillosis; Duration of therapy; Recurrence; Comparative study
资金
- Samsung Medical Center Grant [OTA2002901]
For patients with chronic pulmonary aspergillosis (CPA), extending antifungal therapy beyond 12 months can significantly reduce the recurrence rate.
Objectives: Limited data exist on the optimal treatment duration for chronic pulmonary aspergillosis (CPA). We investigated the treatment outcome and recurrence rate according to treatment duration in CPA patients. Methods: A total of 196 patients who completed at least 6 months of antifungal therapy (99% oral itraconazole) and achieved favorable treatment responses were analyzed. A Cox's proportional hazards regression model was used to adjust for potential confounding factors in the association between the duration of antifungal therapy (6-12 months vs. >= 12 months) and recurrence. Results: All patients were treated with antifungal agents for at least 6 months (median: 12.5, interquartile range: 8.5-18.4 months) and categorized into 6-12 months group (79/196, 40%) and >= 12 months group (117/196, 60%). The 6-12 months group had significantly higher recurrence rates owing to CPA aggravation after the completion of treatment compared with the >= 12 months group (51% vs. 25%, P = 0.003). In a Cox's proportional hazards regression model, treatment duration >= 12 months was independently associated with a lower risk of recurrence (adjusted hazard ratio: 0.48, 95% confidence interval: 0.28-0.80). Conclusions: Our data suggest that prolonging antifungal therapy beyond 12 months could reduce the recurrence rate in CPA patients. (C) 2021 Published by Elsevier Ltd on behalf of The British Infection Association.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据